Time was running out
Our son fought like a warrior accepting all treatments, enduring everything that was thrown at his body and what was humanly possible to endure, but always with a smile, even to the end. During Enguerrand’s fight from 2017 to 2018 we were very close to him, spending a lot of time with him. He received Dasatinib, a type of drug called a cancer growth blocker. Then, after radiotherapy, he received a drug for leukaemia
which does not work for patients with DIPG. We felt there was not enough research and no drugs for DIPG in 2017. During this cancer treatment, he had school at home and once a month he went to school for half a day.